Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients With Molecular Low-Risk Early-Stage Breast Cancer

NCT06671912 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT06671912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06671912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients With Molecular Low-Risk Early-Stage Breast Cancer
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 3
Overall status
Suspended
Start date
February 19, 2025
Completion date
November 30, 2031
Enrollment
1,556 (estimated)
Sites
732

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage 0 breast cancer ajcc v8, anatomic stage 1 breast cancer ajcc v8, anatomic stage iia breast cancer ajcc v8, breast ductal carcinoma in situ, breast lobular carcinoma in situ, estrogen receptor-positive breast carcinoma, her2-negative breast carcinoma